Progyny vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Progyny is a fertility and family building benefits management company providing employer-sponsored fertility coverage that improves outcomes and reduces total fertility spend.
About
Progyny is a publicly traded fertility benefits management company founded in 2008 that has become the leading provider of employer-sponsored fertility benefits in the United States. The company manages fertility coverage for self-insured employers, providing access to a national network of top-tier fertility clinics, a proprietary Smart Cycle benefits design that bundles all medically necessary components of a treatment cycle, and dedicated patient care advocates who guide employees through fertility treatment. Progyny went public on Nasdaq in 2019 under the ticker PGNY and serves over 430 employers covering over 6 million lives including many Fortune 500 companies. The company has published clinical outcomes data demonstrating higher live birth rates, lower multiple birth rates, and lower NICU costs compared to traditional indemnity fertility coverage, translating into healthcare cost savings that offset the benefit cost for employers. Progyny's Smart Cycle design bundles medications, lab tests, and procedures into a single benefit unit that eliminates the piecemeal authorization challenges of traditional insurance coverage. The company competes with Carrot Fertility and Kindbody in the employer fertility benefits market.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.